Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Viking Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Viking Therapeutics, Inc. has 10 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Viking Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Viking Therapeutics, Inc.. Customers appear here when Viking Therapeutics, Inc. names them, or when a company names Viking Therapeutics, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“As partial consideration for the grant of the rights and licenses to the Company under the Master License Agreement, the Company issued to Ligand at the closing of the Company's initial public offering ("IPO") 3,655,964 shares of its common stock having an estimated aggregate value of $ 29.2 million.”
FILING10-K0001193125-26-046876cik 0001607678
“In March 2025, we entered into broad, multi-year manufacturing agreements, or the Manufacturing Agreements, with Corden Pharma Colorado, Inc. and its affiliates, or CordenPharma, covering both the active pharmaceutical ingredient, or API, and final finished product supply for VK2735.”
FILING10-K0001193125-26-046876cik 0001607678
“In March 2025, we entered into broad, multi-year manufacturing agreements, or the Manufacturing Agreements, with Corden Pharma Colorado, Inc. and its affiliates, or CordenPharma, covering both the active pharmaceutical ingredient, or API, and final finished product supply for VK2735.”
FILING10-K0001193125-26-046876cik 0001607678
“In July 2021, we entered into an At-The-Market Equity Offering Sales Agreement, or the ATM Agreement, with Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc. and H.C. Wainwright & Co. LLC, collectively, the Agents, pursuant to which we could offer and sell, from time to time, through or to the Agents, as sales agent or principal, or the ATM Offering, shares of our common stock having an aggregate offering price of up to $125.0 million, or the ATM Shares.”
FILING10-K0001193125-26-046876cik 0001607678
“In July 2021, we entered into an At-The-Market Equity Offering Sales Agreement, or the ATM Agreement, with Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc. and H.C. Wainwright & Co. LLC, collectively, the Agents, pursuant to which we could offer and sell, from time to time, through or to the Agents, as sales agent or principal, or the ATM Offering, shares of our common stock having an aggregate offering price of up to $125.0 million, or the ATM Shares.”
FILING10-K0001193125-26-046876cik 0001607678
“Pursuant to the ATM Agreement Amendment, BTIG, LLC was added as a sales agent for the ATM Offering and the ATM Agreement was amended to provide that the ATM Offering could be conducted off of registration statements on Form S-3 subsequently filed by us.”
FILING10-K0001193125-26-046876cik 0001607678
“Our independent registered public accounting firm, CBIZ CPAs P.C., issued an attestation report on our internal control over financial reporting, as noted below.”
FILING10-K0001193125-26-046876cik 0001607678
“In July 2021, we entered into an At-The-Market Equity Offering Sales Agreement, or the ATM Agreement, with Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc. and H.C. Wainwright & Co. LLC, collectively, the Agents, pursuant to which we could offer and sell, from time to time, through or to the Agents, as sales agent or principal, or the ATM Offering, shares of our common stock having an aggregate offering price of up to $125.0 million, or the ATM Shares.”
FILING10-K0001193125-26-046876cik 0001607678
“In November 2021, the Company entered into an Office Lease (the "Office Lease") with One Pacific Heights. LLC.”
FILING10-K0001193125-26-046876cik 0001607678
“In September 2024 the Company entered into an Office Sublease with TÜV SÜD America Inc. (the "Office Sublease") The Office Sublease is for approximately 6,307 rentable square feet of space located at 9920 Pacific Heights Blvd, Suite 325, San Diego, California 92121 (the "Subleased Premises").”
FILING10-K0001193125-26-046876cik 0001607678
Watchlist prices, news filtered to it, and its next report on your desk.
VKTX (Viking Therapeutics, Inc.) has 10 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TFC +0.84%, in financials.